17413-73-9

Usage

Uses

Used in Chemical and Laboratory Applications:
AKOS B013911 is used as a solvent for its ability to dissolve a wide range of substances, facilitating various chemical reactions and processes in both industrial and laboratory environments.
Used in Perfumery and Personal Care Products:
AKOS B013911 is utilized as an ingredient in perfumes and personal care products, where it contributes to the formulation of scents and the texture of these products, enhancing their performance and appeal.
Used in Industrial Processes:
In various industries, AKOS B013911 is employed to aid in the manufacturing process, often due to its solvent properties that can help in the production of different types of goods, from pharmaceuticals to cosmetics.

InChI:InChI=1/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-4-7(11)6-8/h3-6H,1-2H3,(H,12,13)

Upstream product

• 108-43-0 3-monochlorophenol 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 67-66-3 chloroform 
• 67-64-1 acetone 
• 600-00-0 ethyl 2-bromoisobutyrate 
• 3046-27-3 sodium m-chlorophenoxide 

Downstream Products

• 59227-82-6 ethyl 2-(3-chlorophenoxy)-2-methylpropionate 
• 4878-03-9 2-(3-chloro-phenoxy)-2-methyl-propionyl chloride 

Relevant academic research and scientific papers

Pd(II)-catalyzed ortho - Or meta-C-H olefination of phenol derivatives

A combination of weakly coordinating auxiliaries and ligand acceleration allows for the development of both ortho- and meta-selective C-H olefination of phenol derivatives. These reactions demonstrate the feasibility of directing C-H functionalizations when functional groups are distal to target C-H bonds. The meta-C-H functionalization of electron-rich phenol derivatives is unprecedented and orthogonal to previous electrophilic substitution of phenols in terms of regioselectivity. These methods are also applied to functionalize α-phenoxyacetic acids, a fibrate class of drug scaffolds.

ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.